...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
【24h】

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

机译：口服崩解性奥氮平评价：有效性，患者喜好，依从性和其他特性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Orally disintegrating olanzapine (ODO) is a rapid-dissolving formulation of olanzapine which disintegrates in saliva almost immediately, developed as a convenient and adherence-enhancing alternative to the standard olanzapine-coated tablet (SOT). Clinical studies, which form the basis of this review, have shown ODO and SOT to have similar efficacy and tolerability profiles. However, ODO appears to have a number of advantages over SOT in terms of adherence, patient preference, and reduction in nursing burden. Overall, the existing clinical data suggests that compared to SOT, ODO is not only well-suited for difficult-to-treat, agitated, and/or nonadherent patients but, due to its potential ability to improve adherence and greater patient preference, may also be an appropriate formulation for the majority of patients for which olanzapine is the antipsychotic of choice.
机译：摘要：口服崩解性奥氮平（ODO）是一种快速溶解的奥氮平制剂，几乎可以立即在唾液中崩解，是替代标准奥氮平包衣片（SOT）的便捷且增强粘附力的替代品。构成本综述基础的临床研究表明，ODO和SOT具有相似的疗效和耐受性。但是，在依从性，患者偏爱和减轻护理负担方面，ODO似乎比SOT具有许多优势。总的来说，现有的临床数据表明，与SOT相比，ODO不仅非常适合难以治疗，情绪激动和/或不坚持的患者，而且由于其潜在的改善依从性和更大的患者偏爱的能力，还可能适用于奥氮平为首选抗精神病药的大多数患者的合适制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号